{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:06:39Z","timestamp":1761919599690},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,5,15]],"date-time":"2012-05-15T00:00:00Z","timestamp":1337040000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Neurovirol."],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1007\/s13365-012-0107-0","type":"journal-article","created":{"date-parts":[[2012,5,14]],"date-time":"2012-05-14T18:11:04Z","timestamp":1337019064000},"page":"411-415","source":"Crossref","is-referenced-by-count":7,"title":["Disease-modifying drugs for multiple sclerosis and JC virus expression"],"prefix":"10.1007","volume":"18","author":[{"given":"Craig S.","family":"Miller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sidney A.","family":"Houff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Hopper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Danaher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie A.","family":"Gurwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yushun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nubia","family":"Vega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph R.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,5,15]]},"reference":[{"issue":"2","key":"107_CR1","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1468-1331.2006.01638.x","volume":"14","author":"R Alvarez-Lafuente","year":"2007","unstructured":"Alvarez-Lafuente R, Garcia-Montojo M et al (2007) Interferon-beta treatment and active replication of the JC virus in relapsing-remitting multiple sclerosis patients. Eur J Neurol 14(2):233\u2013236","journal-title":"Eur J Neurol"},{"issue":"Suppl 3","key":"107_CR2","first-page":"257","volume":"42","author":"J Berger","year":"1992","unstructured":"Berger J, Pall L et al (1992) A pilot study of recombinant alpha 2a interferon in the treatment of AIDS-related progressive multifocal leukoencephalopathy (abstract). Neurology 42(Suppl 3):257","journal-title":"Neurology"},{"issue":"1","key":"107_CR3","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1086\/504947","volume":"43","author":"JR Berger","year":"2006","unstructured":"Berger JR, Miller CS et al (2006) JC virus detection in bodily fluids: clues to transmission. Clin Infect Dis 43(1):e9\u2013e12","journal-title":"Clin Infect Dis"},{"key":"107_CR4","unstructured":"BiogenIdec (2011) PML incidence in patients receiving TYSABRI. https:\/\/medinfo.biogenidec.com\/medinfo\/secure\/pmlresource.do?resource=TYSABRIPMLSafetyUpdate . Accessed 26 Nov 2011"},{"issue":"4","key":"107_CR5","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S1369-5274(99)80066-6","volume":"2","author":"CA Biron","year":"1999","unstructured":"Biron CA (1999) Initial and innate responses to viral infections\u2014pattern setting in immunity or disease. Curr Opin Microbiol 2(4):374\u2013381","journal-title":"Curr Opin Microbiol"},{"issue":"5","key":"107_CR6","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/13550280260422758","volume":"8","author":"H Chang","year":"2002","unstructured":"Chang H, Wang M et al (2002) High incidence of JC viruria in JC-seropositive older individuals. J Neurovirol 8(5):447\u2013451","journal-title":"J Neurovirol"},{"issue":"5","key":"107_CR7","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1086\/520518","volume":"196","author":"JK Co","year":"2007","unstructured":"Co JK, Verma S et al (2007) Interferon-alpha and -beta restrict polyomavirus JC replication in primary human fetal glial cells: implications for progressive multifocal leukoencephalopathy therapy. J Infect Dis 196(5):712\u2013718","journal-title":"J Infect Dis"},{"issue":"1","key":"107_CR8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/13550280601094563","volume":"13","author":"S Delbue","year":"2007","unstructured":"Delbue S, Guerini FR et al (2007) JC virus viremia in interferon-beta-treated and untreated Italian multiple sclerosis patients and healthy controls. J Neurovirol 13(1):73\u201377","journal-title":"J Neurovirol"},{"issue":"6","key":"107_CR9","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1086\/597126","volume":"199","author":"A Egli","year":"2009","unstructured":"Egli A, Infanti L et al (2009) Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 199(6):837\u2013846","journal-title":"J Infect Dis"},{"issue":"3","key":"107_CR10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.22128","volume":"68","author":"L Gorelik","year":"2010","unstructured":"Gorelik L, Lerner M et al (2010) Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 68(3):295\u2013303","journal-title":"Ann Neurol"},{"issue":"2","key":"107_CR11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/ni1303","volume":"7","author":"T Kawai","year":"2006","unstructured":"Kawai T, Akira S (2006) Innate immune recognition of viral infection. Nat Immunol 7(2):131\u2013137","journal-title":"Nat Immunol"},{"issue":"4","key":"107_CR12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMoa051782","volume":"353","author":"BK Kleinschmidt-DeMasters","year":"2005","unstructured":"Kleinschmidt-DeMasters BK, Tyler KL (2005) Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353(4):369\u2013374","journal-title":"N Engl J Med"},{"issue":"4","key":"107_CR13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","volume":"353","author":"A Langer-Gould","year":"2005","unstructured":"Langer-Gould A, Atlas SW et al (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353(4):375\u2013381","journal-title":"N Engl J Med"},{"issue":"13","key":"107_CR14","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/jnci\/95.13.1001","volume":"95","author":"J MacKenzie","year":"2003","unstructured":"MacKenzie J, Wilson KS et al (2003) Association between simian virus 40 DNA and lymphoma in the United Kingdom. J Natl Cancer Inst 95(13):1001\u20131003","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"107_CR15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1212\/01.wnl.0000191322.93310.a1","volume":"66","author":"A Nath","year":"2006","unstructured":"Nath A, Venkataramana A et al (2006) Progression of progressive multifocal leukoencephalopathy despite treatment with beta-interferon. Neurology 66(1):149\u2013150","journal-title":"Neurology"},{"issue":"5","key":"107_CR16","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1080\/13550280390241269","volume":"9","author":"E Pagani","year":"2003","unstructured":"Pagani E, Delbue S et al (2003) Molecular analysis of JC virus genotypes circulating among the Italian healthy population. J Neurovirol 9(5):559\u2013566","journal-title":"J Neurovirol"},{"issue":"7","key":"107_CR17","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/j.1469-0691.2004.00882.x","volume":"10","author":"C Polo","year":"2004","unstructured":"Polo C, Perez JL et al (2004) Prevalence and patterns of polyomavirus urinary excretion in immunocompetent adults and children. Clin Microbiol Infect 10(7):640\u2013644","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"107_CR18","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.virol.2005.10.012","volume":"345","author":"S Verma","year":"2006","unstructured":"Verma S, Ziegler K et al (2006) JC virus induces altered patterns of cellular gene expression: interferon-inducible genes as major transcriptional targets. Virology 345(2):457\u2013467","journal-title":"Virology"},{"issue":"9","key":"107_CR19","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa054693","volume":"354","author":"TA Yousry","year":"2006","unstructured":"Yousry TA, Major EO et al (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354(9):924\u2013933","journal-title":"N Engl J Med"}],"container-title":["Journal of NeuroVirology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-012-0107-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13365-012-0107-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-012-0107-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T16:08:26Z","timestamp":1559491706000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13365-012-0107-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,15]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["107"],"URL":"https:\/\/doi.org\/10.1007\/s13365-012-0107-0","relation":{},"ISSN":["1355-0284","1538-2443"],"issn-type":[{"value":"1355-0284","type":"print"},{"value":"1538-2443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,15]]}}}